Home > Inhibitors & Agonists > Wnt/Notch/Hedgehog > GSK-3
Cat. No. Product name CAS No.
DC5144 1-Azakenpaullone Featured

1-Azakenpaullone is a potent and ATP-competitive GSK-3β (glycogen synthase kinase-3β) inhibitor (IC₅₀ = 18 nM).

676596-65-9
DC11827 9-ING-41 Featured

9-ING-41 is a potent glycogen synthase kinase-3 (GSK-3) inhibitor[1]. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β. 9-ING-41 has anticancer activity[2].

1034895-42-5
DC11299 ABC 1183 Featured

ABC1183 is a potent, selective, orally active GSK3α/β and CDK9 inhibitor with IC50 of 327/657 nM and 321 nM (CDK9/cyclin T1), shows growth inhibitory activity against a broad panel of cancer cell lines; decreases cell survival through G2/M arrest and modu

1042735-18-1
DC8263 Bikinin Featured

Bikinin is a strong activator of brassinosteroid (BR) signaling.

188011-69-0
DC7663 BIO Featured

BIO (6-bromoindirubin-3'-oxime) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β, shows >16-fold selectivity over CDK5, also a pan-JAKinhibitor.

667463-62-9
DC7384 CHIR-98014 Featured

CHIR-98014 is a potent GSK-3α/β inhibitor with IC50 of 0.65 nM/0.58 nM, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.

252935-94-7
DC9703 CHIR-99021 HCl Featured

CHIR-99021 HCl is a glycogen synthase kinase 3 beta inhibitor that has antiproliferative activity in vitro and in vivo.

1797989-42-4
DC1023 CHIR-99021 (CT99021) Featured

CHIR-99021 is a glycogen synthase kinase 3 beta inhibitor that has antiproliferative activity in vitro and in vivo.

252917-06-9
DC9726 CP21 (CP21R7) Featured

CP21R7 is a potent and selective GSK-3β inhibitor.

125314-13-8
DC4227 SB216763 Featured

SB 216763 is a potent and selective cell permeable ATP-competitive inhibitor of GSK3α with an IC50 value of 34 nM (similar potency for GSK3β).

280744-09-4
DC2067 TDZD-8 Featured

TDZD-8 is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM.

327036-89-5
DC7680 IM-12 Featured

The GSK3β Inhibitor XIX, IM-12 is a selective GSK-3β inhibitor with IC50 of 53 nM, and also enhances canonical Wnt signalling.

1129669-05-1
DC1063 TWS119 Featured

TWS119 is a GSK-3β inhibitor with IC50 of 30 nM.

601514-19-6
DC7004 AR-A014418(GSK3β Inhibitor VIII) Featured

AR-A014418 is a selective and effective GSK3β inhibitor with an IC 50 value of 104 +/- 27 nM; no significant inhibition on 26 other kinases.

487021-52-3
DC28275 BIP-135

BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor, with IC50s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect.

941575-71-9
DC28365 (Rac)-BRD0705

(Rac)-BRD0705 is a less active racemate of BRD0705. BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor with an IC50 of 66 nM and a Kd of 4.8 μM. BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC50 of 515 nM). BRD0705 can be used for acute myeloid leukemia (AML).

1597440-03-3
DC28691 GSK-3β inhibitor 2

GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active GSK-3β inhibitor with an IC50 of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease.

1702428-31-6
DC40570 KY19382 Featured

KY19382 is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β, with IC50s of 19 and 10 nM, respectively. KY19382 activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β activity. KY19382 can be us

2226664-93-1
DC41037 SAR502250

SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3, with an IC50 of 12 nM for human GSK-3β. SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s disease (AD).

503860-57-9
DC41591 Phospho-Glycogen Synthase Peptide-2(substrate)

Phospho-Glycogen Synthase Peptide-2 (substrate) is peptide substrate?for glycogen synthase kinase-3 (GSK-3) and can be used for affinity purification of protein-serine kinases.

851366-97-7
DC41592 Phospho-Glycogen Synthase Peptide-2(substrate) TFA

Phospho-Glycogen Synthase Peptide-2 (substrate) is peptide substrate?for glycogen synthase kinase-3 (GSK-3) and can be used for affinity purification of protein-serine kinases.

DC41593 2B-(SP)

2B-(SP) is a eIF2B-based substrate for glycogen synthase kinase-3 (GSK-3). 2B-(SP) is readily phosphorylated by both the α and β isoforms of GSK-3.

186901-17-7
DC41594 2B-(SP) (TFA)

2B-(SP) TFA is a eIF2B-based substrate for glycogen synthase kinase-3 (GSK-3). 2B-(SP) TFA is readily phosphorylated by both the α and β isoforms of GSK-3.

DC42060 GSK3 Substrate, α, β subunit

GSK3 Substrate, α, β subunit is peptide substrate for glycogen synthase kinase-3 (GSK-3) and can be used to measure GSK-3 activity.

DC45693 Manzamine A hydrochloride

Manzamine A hydrochloride, a member of the manzamine alkaloids, is a potent, orally active GSK-3β inhibitor (IC50=10.2 μM). Manzamine A hydrochloride shows potent activity against HSV-1 via targeting the viral gene ICP0. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities.

104264-80-4
DC45694 (E/Z)-GSK-3β inhibitor 1

(E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC50 of 4.9 nM.

3367-88-2
DC46485 Cu(II)GTSM

Cu(II)GTSM, a cell-permeable Cu-complex, significantly inhibits GSK3β. Cu(II)GTSM inhibits Amyloid-β oligomers (AβOs) and decreases tau phosphorylation. Cu(II)GTSM also decreases the abundance of Amyloid-β trimers. Cu(II)GTSM is a potential anticancer and antimicrobial agent.

68341-14-0
DC48703 (E/Z)-BIO-acetoxime

(E/Z)-BIO-acetoxime (GSK-3 Inhibitor X) is a potent and selective GSK-3α/β inhibitor, with an IC50 of 10 nM. (E/Z)-BIO-acetoxime shows more than 200-flod selectivity over CDK5/p25, CDK2/cyclin A and CDK1/cyclin B (IC50=2.4, 4.3, 63 μM).

740841-15-0
DC50131 CHIR-98023

CHIR-98023 is a potent, selective and reversible inhibitor of GSK3, with IC50s of 10 nM and 6.7 nM for GSK3α and GSK3β, respectively. CHIR-98023 can improve insulin action and glucose metabolism.

252916-76-0
DC70316 COB-187

COB-187 (COB187) is a highly potent and selective inhibitor of GSK-3 with IC50 of 22/11 nM against GSK-3α/GSK-3β.COB-187 inhibits GSK-3 phosphorylation of β-catenin and, albeit to a lesser extent, glycogen synthase.COB-187 increases the protein level of β-catenin in RAW 264.7 macrophages.COB-187 enhances β-catenin localization to the perinuclear and nuclear region in THP-1 macrophage, does not change the β-catenin mRNA level.COB-187 significantly increases the expression of the Wnt target gene cyclin D1, reduces the phosphorylation of tau in HEK293 cells transfected with tau expression vector.COB-187 inhibits only 3 kinases at >40% in a panel of 414 kinase assays, more selective relative to Tideglusib.

1862177-86-3
DC70465 GSK3β-IN-1a

GSK3β-IN-1a is a relatively selective and potent GSK-3β inhibitor with IC50 of 64 nM; induces replication of growth-arrested R7T1 β cells in a dose-dependent manner with EC50 of 1.1 uM, likely mediates β-cell proliferation through the Wnt signaling pathway.

1139875-74-3
DC71176 TC-G 24 Featured

TC-G 24 (Compound 24) is a potent, selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 17.1 nM.

1257256-44-2
DC71240 ARN25068

ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and DYRK1A to tackle tau hyperphosphorylation.

2649882-80-2
Page 1 / Total 1 FirstPrevNextLastGoto